StockData
Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc. (AGIO) income statement

AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.68−0.21 (-0.70%)

Close on Nov 18, 2026Market cap $1.77BP/E –Yield –

Agios Pharmaceuticals, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
92.0%
Operating margin
-466.8%
Net margin
-418.2%
Return on equity, FY2025
-30.2%

Financial strength

Current ratio
10.22
Debt to equity
–
Debt to assets
–
Cash to current liabilities
141.9%

Valuation

P/E ratio
–
Price to sales
18.02
Price to book
1.73
Dividend yield
–

See a number that looks wrong?